ASCO-GU – another strike against Cabometyx
A triplet did worse than control in first-line kidney cancer.
ASCO-GU – Arcus goes it alone in HIF2α
Casdatifan yields its first median PFS number, but Gilead doesn’t opt in.
ASCO-GU – Corbus backs Chinese data with its own
But investors remain unimpressed with the Nectin-4 ADC Corbus bought for just $7.5m.
ASCO-GU – Pfizer eyes broader Talzenna use
But the overall survival benefit in prostate cancer is still driven by HRR mutations.
ASCO-GU – some backing for Pfizer's EZH2 plan
Phase 1 data give investors a benchmark for mevrometostat's pivotal Mevpro-1 trial.
ASCO-GU – Pfizer looks for bigger bladder cancer invasion
Padcev still looks good in first-line bladder, but Pfizer hopes to make a mark in muscle-invasive disease.
ASCO-GI – ALX resurrects evorpacept
The company reveals fresh biopsy status as a primary endpoint, and declares Aspen-06 a win.
ASCO-GI – a second colorectal win for Bristol's combo
Opdivo and Yervoy succeed again, but the US path remains unclear.
